Compulsory Licensing for Access to Affordable Essential Medicine (Hepatitis C): An Indonesia Perspective
Article Sidebar
Main Article Content
Abstract
Hepatitis C is one of the viral diseases that require special medication. As a viral disease, it means that it requires essential medicine for the treatment. In intellectual property, this becomes one of the issues because of the pricing of essential medicine. The inventor(s) that find this drug is entitled to have an exclusive right to their invention. The exclusive right that given to the inventor(s) is patent. In order to access medicine, it requires the regulations that regulate how to make the patented medicine become accessible especially for Indonesia as a developing country. Under TRIPs Agreement and Indonesian Law, regulates about compulsory licensing. Compulsory licensing is the way to make the patented medicine accessible for patients. However, even though Indonesia has been implemented, this still becomes a problem for poor patients. However, the regulations concerning compulsory licensing remain lack in Indonesia. On the other hand, the determination of royalty for the inventor(s) must proportional.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Abbas MZ and Riaz S, ‘Evolution of the Concept of Compulsory Licensing: A Critical Analysis of Key Developments before and after TRIPS’ (2013) 4(2) Journal Savap Academic Research International
Correa CM and Velasquez G, ‘Access to Medicines: Experiences with Compulsory Licenses and Government Use – The Case of Hepatitis C’ (2019) South Centre Research Paper 85
Lestari SN, ‘Implementasi Compulsory Licensing Terhadap Obat-Obatan dalam Bidang Farmasi di Indonesia’ (Studi Berdasarkan Doha Declaration on the TRIPS Agreement and Public Health) (Thesis, Master Program on Jurisprudence Diponegoro University, Semarang 2012)
Niesporek A, ‘Compulsory Licensing of Pharmaceutical Products & Access to Essential Medicines in Developing Countries’ (Thesis, Linköping University, Sweden 2005)
Samariadi, ‘Pelaksanaan Compulsory Licensing Paten Obat-Obatan Bidang Farmasi di Indonesia Dikaitkan Dengan DOHA Declaration on the TRIPS Agreement and Public Health’ (2016) 1(2) De Lega Lata
Scrutton J, Wallace J, and Wait S, ‘Situation Analysis of Viral Hepatitis in Indonesia: A Policy Report’ (Coalition to Eradicate Viral Hepatitis in Asia Pasific, July 2018)
Sibley A, Han KH, Abourached A, et al. 2015, ‘The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm’ Vol 3 J Viral Hepat 22 Suppl 4
Sulasno, ‘Lisensi Hak Kekayaan Intelektual (HKI) Dalam Perspektif Hukum Perjanjian di Indonesia’ (2012) 3(2) Adil Jurnal Hukum
Umar M, et al, ‘Diagnosis, Management, and Prevention of Hepatitis C in Pakistan 2017’ (2016) 28(4) Journal of Ayub Medical College Abbottabad-Pakistan
Utomo TS, ‘Implikasi Pasal-Pasal Pelindung (The TRIPS Safeguards) Dalam UU Paten Indonesia: Kritik, Evaluasi, dan Saran Dari Perspektif Akses Terhadap Obat Yang Murah dan Terjangkau’ (2007) 14(2) Jurnal Hukum
Wartini S, ‘The Legal Implication of Compulsory License Pharmaceutical Products in the TRIPs Agreement to the Protection of the Right to Health in Developing Countries’ (2018) 18(1) Jurnal Dinamika Hukum
Yuswanto S, ‘Upaya Mewujudkan Alih Teknologi Melalui Waralaba’ (2019) 4(1) UBELAJ
Ardana G, ‘Government Releases Compulsory Licensing Regulation’ accessed 24 November 2019
Badan POM, ‘Badan POM Menyetujui Izin Edar Sofosbuvir, Obat Hepatitis C’ accessed 20 November 2019
Ellen ‘t Hoen and Suerie Moon, ‘Equity Pricing of Essential Medicines in Developing Countries’<https://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/15thoen_e.pdf> accessed 23 November 2019
Global Business Guide Indonesia, ‘Indonesia’s Pharmaceutical Industry is in Rude Health’ (Global Business Guide Indonesia) accessed 28 October 2019
Kementerian dan Kesehatan Republik Indonesia, ‘Situasi Penyakit Hepatitis B di Indonesia Tahun 2017’ Infodatin (Pusat Data dan Informasi Kementerian Kesehatan RI, 2017) <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/Infodatin-situasi-penyakit-hepatitis-B-2018.pdf> accessed 4 September 2019.
Kusuma DR, ‘Jokowi: 95 Persen Bahan Baku Obat Masih Tergantung Impor’ (Kumparan Bisnis, 21 November 2019) <https://kumparan.com/kumparanbisnis/jokowi-95-persen-bahan-baku-obat-masih-tergantung-impor-1sIR5Ov5VZt> accessed 21 November 2019.
Oxford Business Group, ‘Indonesia Bolsters Domestic Pharmaceuticals Production Capacity’ (Oxford Business Group) accessed 9 November 2019.
Prasetyo WB, ‘Obat Hepatitis C di Indonesia Lebih Mahal 10 Kali Lipat Dibanding India’ (Berita Satu, 29 July 2018) <https://www.beritasatu.com/nasional/503222/obat-hepatitis-c-di-indonesia-lebih-mahal-10-kali-lipat-dibanding-india> accessed 21 November 2019.
World Health Organization, ‘Global Report on Access to Hepatitis C Treatment’ (WHO) accessed 28 October 2019
World Health Organization, ‘Hepatitis C’ accessed 5 September 2019
World Intellectual Property Organization, ‘What is Intellectual Property’ accessed 4 September 2019